Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Agenus (AGEN) Presents at Rodman & Renshaw Conference

Agenus Inc. (NASDAQ: AGEN) is an immunology company focused on the discovery and development of novel checkpoint modulators, vaccines and adjuvants to treat cancer and other diseases. Using its proprietary platforms Retrocyte Display™ and SECANT®, the company is currently developing novel antibodies to target a collection of checkpoint proteins – including GITR, OX40, CTLA-4, LAG-3, TIM-3, PD-1 and other undisclosed checkpoints in partnered and internal programs. Agenus’s development pipeline includes Prophage, a heat shock protein vaccine that’s successfully completed phase II studies for the treatment of newly diagnosed glioblastoma multiforme. For more information, visit the company’s website at

Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory, and related services to public and private companies across multiple sectors and regions. Rodman also provides research and sales and trading services to institutional investors. For more information on Rodman & Renshaw, visit
This entry was posted in Rodman and Renshaw Conference. Bookmark the permalink.

Comments are closed.